Navigation Links
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Date:7/30/2008

erent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
5. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
6. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
10. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
11. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Mich. , March 27, 2015  Neogen Corporation ... LLC, has adopted a prearranged trading plan in accordance ... Herbert , Chairman and CEO of Neogen Corporation, is ... of Neogen Corporation common stock. Herbert does ... disclosure was appropriate. The filing is only for a ...
(Date:3/27/2015)... March 27, 2015 WuXi PharmaTech (Cayman) ... R&D capability and technology platform company serving the ... today that an Investigational New Drug (IND) application ... rheumatoid arthritis has been accepted for review by ... In September 2012, MedImmune, the global ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
(Date:3/26/2015)... and CINCINNATI , March ... (LSE: SHP, NASDAQ: SHPG ) and Cincinnati ... broad research collaboration for rare diseases. The goal of ... therapies to treat rare diseases with high unmet ... with Cincinnati Children,s research expertise. As a nationally ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5
... 27 Mediatech, Inc. is settling,into their brand ... land,in Prince William County. Right down the road ... joins other,biotechnology and technology companies, including ATCC in ... The brand new manufacturing plant has been ...
... Amended the Design of the Ofatumumab Pivotal Study in, ... ... 81, COPENHAGEN, September 27 Genmab A/S (OMX:,GEN) announced ... study,of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular,non-Hodgkin,s lymphoma (NHL) to ...
... for October, JACKSONVILLE, Fla., Sept. 27 ... announced today that its,performance/vitality beverage product, AQUISS(TM), will ... to the Oregon border. 7-Eleven,plans a launch of ... sampling campaign to acquaint 7-Eleven,s customers with the,technology ...
Cached Biology Technology:Mediatech Moves to Prince William County Innovation Park 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 2Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study 3Phlo Affiliate Reports AQUISS to be Sold in 450 7-Eleven Stores 2
(Date:3/16/2015)... 2015 Between 16 and ... groundbreaking innovations in biometric identification at the CeBIT ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) ... well at the forefront: the company,s all new ... Germany . BiometricGate is the ...
(Date:3/12/2015)... WINSTON-SALEM, N.C. , March 12, 2015 ... afternoon at Brenner Children,s Hospital, part of Wake Forest ... an outreach initiative for the 2015 ACC Men,s Basketball ... taking pictures with them and getting their autographs. ... Wake Forest Baptist. It is the only children,s hospital ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... September 11, 2012 BiOptix announced continued support of the ... 2012, a leading life sciences showcase event in ... "BiOptix continues to believe in the goals and ... Rick Whitcomb, President and CEO of BiOptix.   "As ...
... a crow and it,ll remember you for years. Crows and ... with negative, as well as positive, feelings. The way the ... also appear to share, according to new research being published ... together are not unlike those that work together in mammals, ...
... found a way to prevent inflammation and bone loss ... of the enzyme GSK3b, which plays an important role ... of UofL School of Dentistry researcher David Scott, PhD, ... journal Molecular Medicine . The finding not only ...
Cached Biology News:BiOptix Participates in Leading Life Sciences Event BioWest 2012 2Crows react to threats in human-like way 2Crows react to threats in human-like way 3
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
...
... first biological reagent that eliminates ... not just by inhibiting growth. ... agent that can be used ... The cytotoxicity of Mynox is ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: